blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2068921

EP2068921 - HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.05.2015
Database last updated on 09.04.2026
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): MT		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
CSL Limited
45 Poplar Road
Parkville VIC 3052 / AU
[2010/52]
Former [2010/10]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
For all designated states
CSL Limited
45 Poplar Road
Parkville, VIC 3052 / AU
Former [2009/25]For all designated states
Merck & Co., Inc.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
For all designated states
CSL Limited
45 Poplar Road
Parkville, VIC 3052 / AU
Inventor(s)01 / NASH, Andrew Donald
185 Peel Street
Kew, Victoria 3084 / AU
02 / BACA, Manuel
720 Market Street East
Gaithersburg, MD 20878 / US
03 / FABRI, Louis Jerry
41 Phipps Crescent
Diamond Creek, Victoria 3089 / AU
04 / ZALLER, Dennis
807 Raritan Road
Scotch Plains, NJ 07076 / US
05 / STROHL, William R.
1086 Tullo Farm Road
Bridgewater, NJ 08807 / US
06 / AN, Zhiqiang
315 Gentry Lane
Ambler, PA 19002 / US
 [2009/25]
Representative(s)Hallybone, Huw George, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2014/28]
Former [2009/51]Hallybone, Huw George, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Former [2009/25]Hallybone, Huw George, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date07868508.819.10.2007
[2009/25]
WO2007US81879
Priority number, dateUS20060852884P19.10.2006         Original published format: US 852884 P
[2009/25]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008060813
Date:22.05.2008
Language:EN
[2008/21]
Type: A2 Application without search report 
No.:EP2068921
Date:17.06.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 22.05.2008 takes the place of the publication of the European patent application.
[2009/25]
Type: B1 Patent specification 
No.:EP2068921
Date:09.07.2014
Language:EN
[2014/28]
Search report(s)International search report - published on:US28.08.2008
(Supplementary) European search report - dispatched on:EP01.06.2010
ClassificationIPC:C07K16/28, C12N5/20, A61K39/395, A61P35/00, A61P37/00
[2010/26]
CPC:
C07K16/2866 (EP,US); A61P1/00 (EP); A61P1/04 (EP);
A61P11/00 (EP); A61P11/02 (EP); A61P11/06 (EP);
A61P17/00 (EP); A61P17/04 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P37/00 (EP); A61P37/08 (EP); A61P43/00 (EP);
C12P21/005 (US); C07K2317/21 (EP,US); C07K2317/33 (EP,US);
C07K2317/56 (EP,US); C07K2317/565 (EP,US); C07K2317/71 (EP,US);
C07K2317/76 (EP,US); C07K2317/92 (EP,US); C07K2319/43 (EP,US) (-)
Former IPC [2009/25]A61K39/395
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/25]
TitleGerman:HOCHAFFINE ANTIKÖRPER-ANTAGONISTEN DES INTERLEUKIN-13-REZEPTORS ALPHA 1[2009/25]
English:HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1[2009/25]
French:ANTICORPS ANTAGONISTES DE HAUTE AFFINITÉ DIRIGÉS CONTRE LE RÉCEPTEUR ALPHA 1 DE L'INTERLEUKINE-13[2009/25]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase30.03.2009National basic fee paid 
30.03.2009Search fee paid 
30.03.2009Designation fee(s) paid 
30.03.2009Examination fee paid 
Examination procedure30.03.2009Examination requested  [2009/25]
20.12.2010Amendment by applicant (claims and/or description)
18.11.2011Despatch of a communication from the examining division (Time limit: M06)
27.06.2012Reply to a communication from the examining division
19.03.2013Despatch of a communication from the examining division (Time limit: M02)
24.05.2013Reply to a communication from the examining division
18.06.2013Despatch of a communication from the examining division (Time limit: M02)
01.08.2013Reply to a communication from the examining division
03.10.2013Communication of intention to grant the patent
24.03.2014Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
29.05.2014Fee for grant paid
29.05.2014Fee for publishing/printing paid
29.05.2014Receipt of the translation of the claim(s)
Divisional application(s)EP14175846.6  / EP2829551
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.11.2011
Opposition(s)10.04.2015No opposition filed within time limit [2015/25]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
29.05.2014Request for further processing filed
29.05.2014Full payment received (date of receipt of payment)
Request granted
12.06.2014Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
27.06.2012Request for further processing filed
27.06.2012Full payment received (date of receipt of payment)
Request granted
12.07.2012Decision despatched
Fees paidRenewal fee
13.10.2009Renewal fee patent year 03
12.10.2010Renewal fee patent year 04
11.10.2011Renewal fee patent year 05
11.10.2012Renewal fee patent year 06
15.10.2013Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.10.2007
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
MT09.07.2014
RO09.07.2014
SI09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
[2016/33]
Former [2016/32]HU19.10.2007
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
RO09.07.2014
SI09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/50]CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
RO09.07.2014
SI09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/27]CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
RO09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/23]CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
RO09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/22]CY09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
RO09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/12]CY09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/11]CY09.07.2014
FI09.07.2014
LT09.07.2014
BG09.10.2014
GR10.10.2014
PT10.11.2014
Former [2015/10]FI09.07.2014
LT09.07.2014
BG09.10.2014
Former [2015/09]FI09.07.2014
LT09.07.2014
Former [2015/08]LT09.07.2014
Documents cited:Search[IDY] WO2006072564  (HOFFMANN LA ROCHE et al.) [ID] 1,4,5,9,10,13,14,16-18 * page 7, lines 1-4; example -; tables 2-3 *[Y] 2,3,6-8,11,12,15
 [IY] EP1449851  (MOCHIDA PHARM CO LTD et al.) [I] 1,4,5,9,10,13,14,16-18 * page 15, paragraph 0086; example -; table 2 *[Y] 2,3,6-8,11,12,15
 [YD] US6468528  (MAK TAK W et al.) [YD] 15 * column 2, line 42 - column 3, line 3; example 4; claims 15-16 *
 [Y] WO2006055178  (MERCK & CO INC et al.) [Y] 2,3,6-8,11,12 * figures 11C, 11D, 11G, 11R, 11S, 12; example 19; sequences 154,155,158,169,170,254 *
 [A] US2006140948  (FOLTZ IAN et al.) [A] 13-15 * paragraphs [0124] , [ 0176] - [0177]; example 15 *
 [IDY]   KRAUSE S ET AL: "Blockade of interleukin-13-mediated cell activation by a novel inhibitory antibody to human IL-13 receptor alpha1", MOLECULAR IMMUNOLOGY, PERGAMON, GB LNKD- DOI:10.1016/J.MOLIMM.2005.11.001, vol. 43, no. 11, 1 April 2006 (2006-04-01), pages 1799 - 1807, XP025037314, ISSN: 0161-5890, [retrieved on 20060401] [ID] 1,4,5,9,10,13,14,16-18 * abstract * * items 3.3 and 3.4 * [Y] 2,3,6-8,11,12,15

DOI:   http://dx.doi.org/10.1016/j.molimm.2005.11.001
 [T]   GENOVAC: "Product Data Sheet anti-human IL13 receptor (IL13-R) monoclonal antibody", INTERNET CITATION, 1 January 2007 (2007-01-01), pages 1 - 2, XP007913032, Retrieved from the Internet [retrieved on 20100511] [T] * the whole document *
by applicant  HERSHEY ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 111, no. 4, 2003, pages 677 - 690
   GRUNIG ET AL., SCIENCE, vol. 282, no. 5397, 1998, pages 2261 - 2263
   MATTES ET AL., J. IMMUNOL., vol. 167, no. 3, 2001, pages 1683 - 1692
   FULKERSON ET AL., AM. J. RESPIR. CELL. MOL. BIOL., vol. 35, no. 3, 2006, pages 337 - 346
   WILLS-KARP ET AL., SCIENCE, vol. 282, no. 5397, 1998, pages 2258 - 2261
   REIMAN ET AL., INFECT. IMMUN., vol. 74, no. 3, 2006, pages 1471 - 1479
   KAVIRATNE ET AL., J. IMMUNOL., vol. 173, no. 6, 2004, pages 4020 - 4029
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.